From the Departments of Medicine (M.T., N.P.) and Public Health Sciences (M.T.) and the Division of Critical Care Medicine (N.P.), University of Alberta, Edmonton; and the Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB (B.M.) — both in Canada.
Supported by an Interdisciplinary Team Grant from the Alberta Heritage Foundation for Medical Research and a joint initiative between Alberta Health and Wellness and the University of Alberta and the University of Calgary. Drs. Tonelli and Manns were also supported by New Investigator Awards from the Canadian Institutes of Health Research, and Dr. Tonelli by a Health Scholar award from the Alberta Heritage Foundation for Medical Research.
Drs. Tonelli and Manns report receiving a grant to the Alberta Kidney Disease Network, which is funded in part by Amgen and Merck Frosst Canada; Dr. Tonelli, receiving a grant jointly funded by the Canadian Institutes of Health Research and Abbott Laboratories; and Dr. Pannu, receiving a lecture fee from Amgen. No other potential conflict of interest relevant to this article was reported. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
